Dragonfly Therapeutics to Present Preclinical Data on DF6215 and DF9001 at SITC Annual Conference

Dragonfly Therapeutics, Inc., a biotech company focused on developing innovative immunotherapies, has announced its participation at the Society for Immunotherapy of Cancer (SITC) Annual Conference. The company will present posters that showcase preclinical data for two of their clinical-stage assets, DF6215 and DF9001, which are being investigated for their potential to treat advanced solid tumors.

DF6215 is an engineered IL-2 cytokine designed to enhance immune response against tumors. In preclinical studies, DF6215 demonstrated significant therapeutic benefits over a non-alpha IL-2 in the CT26 mouse tumor model. Additionally, DF6215 was shown to work synergistically with PD-1 blockade in the "cold" B16F10 melanoma tumor model, improving anti-tumor efficacy without increasing toxicity. This suggests that DF6215 could potentially enhance the effects of existing immunotherapies by boosting the immune system's ability to fight cancer.

DF9001 is an EGFR-targeting TriNKET, which stands for Tri-specific Natural Killer cell Engager Therapy. This novel therapy is designed to inhibit EGFR signals, which are often implicated in the growth and survival of various cancers, including Non-Small Cell Lung Cancer, Renal Cell Carcinoma, and Head and Neck Squamous Cell Carcinoma. In a xenograft mice model, DF9001 exhibited superior anti-tumor activity compared to cetuximab, a current standard treatment. Moreover, DF9001 was effective even without EGFR signal inhibition, owing to its ability to recruit and activate immune effector cells, which play a critical role in targeting and eliminating cancer cells.

The promising preclinical results for both DF6215 and DF9001 underscore Dragonfly Therapeutics' commitment to advancing the field of immunotherapy by developing treatments that leverage the body's immune system to combat cancer. As these therapies progress through clinical trials, they hold the potential to offer new hope for patients with advanced solid tumors.